OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
Summary
OpenAI has acquired Orchestra Bio to integrate its drug-discovery agents into the Rosalind life sciences platform. The creator of ChatGPT aims to leverage artificial technology to significantly reduce the extensive timeframe currently required to develop new medicines.
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
Source: Read the full story at Decrypt
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.